Markets:

Overview

News

Currencies

International

Treasuries

Pfizer (NY:PFE)

26.18 +0.32 (+1.26%)

Streaming Delayed Price Updated: 3:21 PM EST, Jan 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

This Beaten-Down Biotech Is Showing Signs of Life. Is It a Buy? ↗

Today 8:50 EST

The business may not be as strong as its performance this year suggests.

Via The Motley Fool

3 High-Yield Stocks to Buy Hand Over Fist in January ↗

Today 7:23 EST

If you like dividend stocks, here's a high yielder, a Dividend King, and a turnaround story to consider as January comes to a close.

Via The Motley Fool

Topics Economy

This Could Be 1 of the Best Pharmaceutical Stock-Buying Opportunities I've Seen in Years ↗

January 28, 2026

After a years-long revenue drought, there's a light at the end of the tunnel.

Via The Motley Fool

Constitutional Cliffhanger: Supreme Court Set to Rule on Executive Tariff Power as Market Braces for Margin Volatility

January 28, 2026

As the final days of January 2026 unfold, the financial world is fixed on the steps of the U.S. Supreme Court. A landmark decision in the consolidated cases of Learning Resources, Inc. v. Trump and...

Via MarketMinute

Topics Economy Government World Trade

TRAW Stock Slides In Volatile Session – What’s The Latest On Its Phase 2 Trial For COVID-19 Treatment? ↗

January 26, 2026

Via Stocktwits

FDA Codifies AI’s Role in Drug Production: New 2026 Guidelines Set Global Standard for Pharma Safety and Efficiency

January 28, 2026

In a landmark shift for the biotechnology and pharmaceutical industries, the U.S. Food and Drug Administration (FDA) has officially entered what experts call the “Enforcement Era” of artificial...

Via TokenRing AI

Topics Artificial Intelligence Economy

What's going on in today's session: S&P500 most active stocks ↗

January 28, 2026

Via Chartmill

Looking for the most active stocks in the S&P500 index on Tuesday? ↗

January 27, 2026

Via Chartmill

The Analyst Verdict: Pfizer In The Eyes Of 7 Experts ↗

January 27, 2026

Via Benzinga

2 Biotech Stocks Set to Rebound in 2026 ↗

January 27, 2026

They could perhaps see sustained runs beyond this year.

Via The Motley Fool

Why Is Pfizer Stock Rising Tuesday? ↗

January 27, 2026

Pfizer Inc. (PFE) shares are trading higher on Tuesday, as the stock benefits from a price target increase at Cantor Fitzgerald. The firm raised its target to $27 from $24, providing a catalyst for the...

Via Benzinga

Aclaris Hair Loss Drug Shows Faster Results Than Pfizer's Drug ↗

January 27, 2026

Aclaris Therapeutics reported early study results showing its ATI-2138 drug drove rapid and lasting hair regrowth, outperforming Pfizer's Litfulo in a severe hair loss mouse model.

Via Benzinga

Where Will Eli Lilly Be in 10 Years? ↗

January 27, 2026

Eli Lilly is the leader in GLP-1 weight loss drugs today, but that advantage won't last forever.

Via The Motley Fool

Topics ETFs Intellectual Property

What Are Wall Street Analysts' Target Price for Pfizer Stock?

January 27, 2026

Pfizer has lagged the broader market over the past year, and analysts remain cautious about its future outlook.

Via Barchart.com

Topics ETFs

What's going on in today's session: S&P500 most active stocks ↗

January 26, 2026

Via Chartmill

The Post-Keytruda Pivot: Inside Merck’s Strategic Evolution and the RVMD Landscape

January 26, 2026

As of January 26, 2026, Merck & Co. (NYSE: MRK) stands at the most critical juncture in its 135-year history. Known globally for its dominant oncology franchise and robust vaccine portfolio, the...

Via Finterra

Topics Artificial Intelligence Economy Intellectual Property

Recent Report Shows That Rep. French Hill Sold Up to $365K Worth of Pfizer Stock ↗

January 26, 2026

Via Benzinga

The $6 Billion Disconnect: Why Revolution Medicines (RVMD) Plunged 20% After Merck Talks Collapsed

January 26, 2026

The biotechnology sector has always been a high-stakes arena where clinical success can create multi-billion-dollar empires overnight, and a failed negotiation can erase a fifth of a company’s market...

Via Finterra

Topics Economy Initial Public Offering

The Best Stocks to Invest $40 in to Start the New Year Off Right ↗

January 24, 2026

Both could reward patient investors down the line.

Via The Motley Fool

Topics Intellectual Property World Trade

AGG vs. VCIT: The Same Tiny Fee, Completely Different Holdings ↗

January 24, 2026

Explore how portfolio breadth and risk profiles set these two leading bond ETFs apart for income-focused investors.

Via The Motley Fool

Topics Bonds ETFs

Pfizer CEO Calls RFK's Vaccine Views Anti-Science, Warns US Falling Behind China In Health Research ↗

January 23, 2026

Pfizer CEO Albert Bourla criticizes RFK's vaccine stance, warns US health research is losing ground to China, and urges stronger global competitiveness.

Via Benzinga

The HSR Paradox: How 'Early Termination' is Reshaping the 2026 M&A Landscape

January 23, 2026

A year after the most radical transformation of U.S. antitrust filing rules in nearly half a century, the domestic merger and acquisition (M&A) market is finally finding its rhythm. The Federal Trade...

Via MarketMinute

Topics Earnings Economy

The Top Stock to Buy With $30 for 2026 ↗

January 23, 2026

It's a great opportunity to "buy low."

Via The Motley Fool

Topics Intellectual Property

Stability Meets Scale: Why Johnson & Johnson is Poised for a Breakout 2026

January 23, 2026

As of January 23, 2026, Johnson & Johnson (NYSE:JNJ) finds itself at a historic crossroads. After spending much of 2025 navigating the "patent cliff" of its blockbuster drug Stelara and finalizing its...

Via MarketMinute

Topics Artificial Intelligence Bankruptcy Economy

Viking Therapeutics (VKTX) 2026 Deep Dive: Challenging the Obesity Duopoly

January 23, 2026

Date: January 23, 2026 Introduction In the high-stakes arena of metabolic medicine, few companies have generated as much speculative fervor and clinical awe as Viking Therapeutics (NASDAQ: VKTX). As of...

Via Finterra

Topics Intellectual Property

The Trillion-Dollar Heavyweight: Eli Lilly Surge Signals Unrivaled Dominance in the GLP-1 Era

January 22, 2026

Eli Lilly (NYSE: LLY) has once again demonstrated its resilience and market-leading strength, logging a significant 5.2% gain over the last five trading days as of January 22, 2026. This recent rally...

Via MarketMinute

Topics Economy

The Biotech Renaissance: Scientific Breakthroughs and M&A Frenzy Spark a New Bull Market

January 22, 2026

The U.S. biotech sector has officially entered a new golden age. As of January 22, 2026, the industry is witnessing a "renaissance" that has effectively erased the memories of the grueling three-year...

Via MarketMinute

Topics Artificial Intelligence ETFs Initial Public Offering

Stay informed about the most active stocks in the S&P500 index on Thursday's session. ↗

January 22, 2026

Via Chartmill

Moderna’s 2026 Pivot: From Pandemic Pioneer to Oncology Powerhouse

January 22, 2026

As of January 22, 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a pivotal crossroads in its corporate evolution. Once the poster child for the global pandemic response, the Cambridge-based...

Via Finterra

Topics Artificial Intelligence Economy Intellectual Property

How Is The Market Feeling About Pfizer Inc? ↗

January 22, 2026

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.